3B BlackBio Dx Ltd532067Corporate

Healthcare Service Provider Latest results: Jun 2026 14 quarters of data
₹1,296.00
MCap ₹1,166 Cr · P/E 20.7
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹33 Cr
Sales · Jun 2026
+50.7% YoY
₹9 Cr
Operating Profit · Jun 2026
-28.0% YoY
25.4%
OPM % · Jun 2026
-52.3% YoY
₹9 Cr
Net Profit · Jun 2026
-29.0% YoY
₹10.48
EPS · Jun 2026
-28.6% YoY

📝 3B BlackBio Dx Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

3B BlackBio Dx Ltd reported revenue of ₹33 crore for the quarter ended June 2026 (Q1 FY27), up 50.7% from ₹22 crore in the same quarter last year, and down 5.5% sequentially over the March 2026 quarter.

Net profit fell 29.0% year-on-year to ₹9 crore, from ₹13 crore. Earnings per share (EPS) came in at ₹10.48.

Operating profit stood at ₹9 crore — an operating margin (OPM) of 25.4%, compared with 53.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, 3B BlackBio Dx Ltd posted revenue of ₹142 crore, a growth of 47.1% over FY25, with a net profit of ₹60 crore (up 25.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹153 crore with a net profit of ₹56 crore.

Valuation snapshot

At the current price of ₹1,296.00, 532067 has a market capitalisation of ₹1,166 crore and a trailing P/E of about 20.7.

Within the Healthcare Service Provider industry, it is the 2nd-largest of the 20 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 40.95%, foreign institutional investors (FIIs) 2.50%, domestic institutional investors (DIIs) 2.15%, public shareholders 54.40% of 3B BlackBio Dx Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,166 Cr
Current Price ?
₹1,296.0
P/E ?
20.73below ind
Industry P/E ?
22.50
P/B ?
3.59
P/S ?
7.62
P/FCF ?
43.20
Enterprise Value ?
₹1,169 Cr
EV/EBITDA ?
21.87
PEG ?
0.67
Earnings Yield ?
4.0%
Dividend Yield ?
0.31%
Profitability & Returns
Sales (TTM) ?
₹153 Cr
OPM ?
34.9%
Profit after tax (TTM) ?
₹56 Cr
EPS (TTM) ?
₹62.52
ROCE ?
25.0%
ROE ?
17.3%
ROA ?
14.9%
Growth
Sales — latest qtr ?
₹33 Cr
PAT — latest qtr ?
₹9 Cr
YoY qtr sales growth ?
50.7%
YoY qtr profit growth ?
-29.0%
Sales growth (3y) ?
32%
Sales growth (5y) ?
-9%
Profit growth (3y) ?
31%
Profit growth (5y) ?
-12%
Financial Health
Debt ?
₹3 Cr
Debt to Equity ?
0.01
Interest Coverage ?
215.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
40.95%
Change in promoter holding ?
-0.33%
Pledged percentage ?
N/A
Market
Return 3 months ?
7.8%
Return 6 months ?
0.0%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1814191823192925222234503533 +50.7% -5.5%
Operating Profit 768910111615812152289 -28.0% +0.4%
Other Income 133344335466106 +42.2% -39.5%
Interest 00000000000000 +925.0% +2.5%
Depreciation 00000000001041 +380.0% -65.5%
Profit Before Tax 89101114141918131620271513 -16.6% -9.8%
Net Profit 578991115138131522109 -29.0% -8.5%
EPS 7.729.7110.4610.1610.3312.9717.0715.619.7914.6717.1425.3211.1410.48 -28.6% -5.9%
OPM % 41.2% 45.1% 40.6% 50.2% 43.0% 56.4% 55.5% 59.4% 35.2% 53.2% 43.5% 43.1% 24.0% 25.4% -52.3% +5.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹96 Cr ₹142 Cr ₹153 Cr +47.1%
Operating Profit ₹50 Cr ₹57 Cr ₹53 Cr +13.3%
OPM % 51.94% 40.00% 34.90% -23.0%
NPM % 49.45% 42.24% 36.74% -14.6%
Other Income ₹15 Cr ₹26 Cr ₹27 Cr +69.6%
Depreciation ₹1 Cr ₹5 Cr ₹6 Cr +370.6%
Interest ₹0 Cr ₹0 Cr ₹0 Cr +140.0%
EBIT ₹49 Cr ₹52 Cr ₹47 Cr +5.3%
PBT ₹64 Cr ₹77 Cr ₹74 Cr +20.3%
Tax — — ₹4 Cr —
Net Profit ₹48 Cr ₹60 Cr ₹56 Cr +25.7%
EPS ₹55.44 ₹68.27 ₹64.08 +23.1%
Material Cost — — ₹8 Cr —
Employee Cost — — ₹9 Cr —
Extraordinary Items — — ₹0 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 9999 +0.0%
Reserves 185214260316 +21.5%
Borrowings 2103 —
Other Liabilities 19242751 +88.9%
Total Liabilities 214248296378 +27.7%
Fixed Assets 87728 +300.0%
CWIP 0000 —
Investments 92117156158 +1.3%
Other Assets 114123132193 +46.2%
Total Assets 214248296378 +27.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 20274352 +20.9%
Cash from Investing Activity 15-20-33-24 +27.3%
Cash from Financing Activity -5-4-3-1 +66.7%
Net Cash Flow 303728 +300.0%
Free Cash Flow 18264227 -35.7%
CFO/OP 100%115%116%121% +4.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 200179138129 -6.5%
Inventory Days 164141124187 +50.8%
Days Payable 69662870 +150.0%
Cash Conversion Cycle 296253235245 +4.3%
Working Capital Days 241215169143 -15.4%
ROCE % 19%21%26%25% -3.8%

👥 Shareholding (latest 4 periods)

Metric Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 41.28%41.27%40.94%40.95% +0.0%
FIIs 2.64%2.57%2.57%2.50% -2.7%
DIIs 1.82%1.87%1.98%2.15% +8.6%
Public 54.26%54.27%54.50%54.40% -0.2%
No. of Shareholders 10,70910,50710,61611,049 +4.1%

⚖️ Peer comparison

Industry: Healthcare Service Provider · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 NEPHROPLUS Nephrocare Health ₹673.00 6,768 78.9 1,054 85 22.8% 8.1% — — 23.6% 33.2%
2 532067 3B BlackBio ₹1,205.90 1,166 18.8 153 56 34.9% 36.7% 47.1% 25.7% 50.7% -29.0%
3 514330 One Global ₹139.00 1,043 3.7 513 74 19.1% 14.5% 311.6% 288.9% 16.8% 43.0%
4 HEALTHX Health X ₹306.95 976 — 0 -1 -390.4% -376.2% — — -20.0% -367.5%
5 526546 Choksi Laboratories ₹61.93 146 19.9 47 2 26.8% 4.6% 10.1% 28.8% 7.5% 49.3%
6 540788 Aspira Pathlab ₹31.00 107 — 26 -0 3.8% -1.7% 13.5% -97.1% 17.5% -108.5%
7 530897 NG Industries ₹165.30 39 28.7 17 2 11.1% 11.4% -0.9% -77.7% 13.8% 104.3%
8 524602 Bandaram Pharma ₹30.99 33 162.8 79 1 4.8% 1.5% 70.2% -46.9% 195.7% 3322.0%
9 524548 Sharma East ₹50.09 32 13.9 37 1 9.6% 3.2% 20.3% 0.0% 13.7% -18.7%
10 542248 Deccan Health ₹35.53 30 34.8 82 3 6.4% 3.1% 9.1% 115.7% -0.3% 21.3%
11 539267 Samsrita Labs ₹17.13 28 — — — — — — — — —
12 523489 Chennai Meenakshi ₹34.47 28 — 37 -0 1.5% -1.1% 6.4% 16.1% -0.7% 100.4%
13 539428 Tejnaksh Healthcare ₹23.46 27 38.5 11 1 26.5% 11.3% -16.3% -47.5% 0.5% 24.1%
14 526139 Transgene Biotek ₹9.56 21 — 0 -2 -223.0% -766.2% -25.9% -146.3% 20.0% 9.5%
15 516110 Family Care ₹7.44 11 — 0 -8 -1321.3% -3505.7% -97.3% 80.3% 150.0% 39.5%
16 534422 Looks Health ₹5.73 10 177.4 0 0 41.2% 7.5% -2.6% 0.0% 75.7% —
17 531043 Dhanvantri Jeevan ₹19.95 10 16.1 28 1 3.2% 1.8% 14.2% -23.5% 41.6% 200.0%
18 526504 Dolphin Medical ₹1.85 10 5.2 1 0 13.0% 7.4% -2.6% 333.3% 21.2% -40.7%
19 541299 Dr Lalchandani ₹27.60 7 345.0 4 0 9.3% 1.7% — — -8.6% -148.1%
20 526187 Ashram Online.Com ₹6.29 7 — 1 -0 -74.9% -20.3% 33.3% -71.4% 31.6% 40.2%
❓ Frequently asked questions
What was 3B BlackBio Dx Ltd's revenue in Q1 FY27?
3B BlackBio Dx Ltd reported revenue of ₹33 crore for the quarter ended June 2026 (Q1 FY27), up 50.7% from ₹22 crore in the same quarter last year, and down 5.5% sequentially over the March 2026 quarter.
What was 3B BlackBio Dx Ltd's net profit in Q1 FY27?
Net profit fell 29.0% year-on-year to ₹9 crore, from ₹13 crore. Earnings per share (EPS) came in at ₹10.48.
What is 532067's market capitalisation and P/E ratio?
At the current price of ₹1,296.00, 532067 has a market capitalisation of ₹1,166 crore and a trailing P/E of about 20.7.
Who owns 3B BlackBio Dx Ltd? (shareholding pattern)
As of Jun 2026, promoters held 40.95%, foreign institutional investors (FIIs) 2.50%, domestic institutional investors (DIIs) 2.15%, public shareholders 54.40% of 3B BlackBio Dx Ltd.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI